Drugs / Allogenic Mesenchymal stem cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02731586 | Jan 2016 → Dec 2017 | — | Sri Sai College of Dental Surgery and Research Centre | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02857010 | Feb 2016 → Feb 2018 | liver disorder | Pere Gines | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic Mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02731586 ↗ |
| Modality | Cell therapy | “Human mesenchymal stem cells (hMSC) are primary cells which can be successfully used for infusion purpose.” NCT02731586 ↗ |
| Route | Other | “infusion of stem cells at the osteotomy site” NCT02731586 ↗ |